<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-G0B7Q178</identifier><date>2023</date><creator>Mencinger, Marina</creator><relation>documents/doc/G/URN_NBN_SI_doc-G0B7Q178_001.pdf</relation><relation>documents/doc/G/URN_NBN_SI_doc-G0B7Q178_001.txt</relation><format format_type="type">article</format><format format_type="extent">Str. 123-128</format><identifier identifier_type="COBISSID_HOST">140287491</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-G0B7Q178</identifier><language>slv</language><publisher publisher_location="Ljubljana">Onkološki inštitut</publisher><publisher publisher_location="Ljubljana">Sekcija za internistično onkologijo SZD</publisher><source>Šola raka prostate</source><rights>InC</rights><subject language_type_id="slv">kemoterapija</subject><subject language_type_id="slv">onkološko zdravljenje</subject><subject language_type_id="slv">rak prostate</subject><title>Metastatic castration-resistant prostate cancer</title><title>Metastatski, na kastracijo odporen rak prostate</title><title>radionuclides, immune check-point inhibitor and poly (ADP-ribose) polymerase inhibitors</title><title>radionuklidi, zaviralec imunskih nadzornih točk in zaviralci poli-ADP-riboza polimeraze</title></Record>